1931–1988

Free Radicals and Multisystem Aging

Research reframed aging as a consequence of oxidative damage driven by free radicals. Evolutionary perspectives introduced antagonistic pleiotropy to explain life-history trade-offs and late-life decline. Investigations coalesced around a multisystem framework linking vascular, renal, neural, and endocrine changes. Studies on immunosenescence and dietary restriction demonstrated conserved processes and catalyzed translational research.

Period 1931-1960: Researchers examined multisystem vascular decline[1][2][3][4][5][6][7], cellular senescence[8][9][10][11][12], dietary longevity models[13][9][14][15], biochemical markers[16][2][4][6], and tissue morphology[17][1][11][7]. Seminal works established the free radical theory[18], antagonistic pleiotropy[19], growth-longevity trade-offs[20], and multi-stage carcinogenesis[21]. Period 1961-1988: Vascular, immune, cellular, neurological, and hormonal paradigms linked multi-organ aging processes[22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. Landmark disease, evolutionary, and dietary restriction studies shaped geriatric medicine and longevity science[40][41][42][43][44].

1989–2002

Metabolic and Telomeric Aging Paradigms

Aging research framed metabolism as a central regulator through dietary restriction and mitochondrial function. Telomere dynamics and cellular senescence emerged as concrete mechanisms linking metabolic state to aging and tumor suppression. Telomerase reactivation extended the replicative lifespan of normal human cells. Reduced insulin signaling and yeast longevity pathways established a unifying paradigm connecting genome integrity and metabolic regulation.

Period 1989-1995: Mitochondrial dysfunction, oxidative damage, telomere attrition, neurovascular decline, and endocrine shifts drive cellular aging[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. Dietary restriction, telomere tracking, redox theories, and senescence markers fundamentally shaped longevity and therapeutic research[16][14][7][17]. Period 1996-2002: Telomerase reactivation, p16INK4a-linked senescence, free radical modulation, brain vulnerability, and endocrine regulation define aging dynamics[18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]. Frailty phenotypes, telomerase life extension, reduced IGF-1 signaling, SIR2 pathways, and protein oxidation shape longevity therapies[36][18][37][38][39].

2003–2009

Systems Biology of Aging

Aging research converged on a systems-level view linking endocrine signals, genome maintenance, and mitochondrial function as interdependent determinants of lifespan. Insulin and IGF-like signaling pathways together with longevity factors such as klotho emerged as central systemic regulators. Genomic stability and DNA damage responses connected telomere dynamics and senescence programs through key tumor suppressor axes. Mitochondrial dysfunction and oxidative stress drove cellular decline, while brain aging phenotypes illustrated how these processes shape cognitive trajectories.

Period 2003-2009: Endocrine signaling, genome stability, mitochondrial function, and brain aging intersect as integrated drivers of mammalian lifespan[1][2][3][4][5][6][7][8][9][10][11][12][13]. Landmark discoveries on klotho[2], cellular senescence[7], inflammaging[14], mitochondrial dynamics[15], and DNA repair[16] shaped subsequent aging therapies.

2010–2023

Senescence and Metabolic Aging Frameworks

Cellular senescence and the senescence-associated secretory phenotype emerged as central drivers of tissue dysfunction and chronic inflammation. Researchers linked metabolic pathways, autophagy, and mitochondrial maintenance to longevity through interventions targeting nutrient-sensing networks. The hallmarks of aging framework unified diverse biological phenomena into a coherent model that catalyzed biomarker and therapeutic development. Inflammaging and ferroptosis further expanded target discovery by connecting chronic inflammation and redox processes to multi-system decline.

Period 2010-2016: Nutrient-sensing pathways, cellular senescence, and nuclear-mitochondrial crosstalk drive tissue dysfunction, mitigated by senolytics and metabolic interventions[1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Unifying frameworks, senolytic paradigms, clinical gait biomarkers, and global health policies profoundly shaped subsequent translational aging research[15][16][17][18]. Period 2017-2023: Researchers coupled the SASP, inflammaging, autophagy, and glial remodeling to map systemic tissue dysfunction[19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]. Seminal frameworks redefined aging via senolytics, chronic inflammation, ferroptosis, and expanded biological hallmarks[19][26][36][37].

Free Radicals and Multisystem Aging era

Sidney Katz and Denham Harman

Sidney Katz[1], working at Case Western Reserve University[3] and Michigan State University[4], helped shape the multisystem investigation of older populations. Through Studies of Illness in the Aged[7], this work advanced our understanding of functional health status and chronic disease burdens during late-life decline. Denham Harman[2], affiliated with the University of Nebraska at Omaha[5] and the University of Nebraska Medical Center[6], established the oxidative damage theory of aging. This foundational contribution was articulated in Aging: A Theory Based on Free Radical and Radiation Chemistry[8] and further elaborated in The aging process.[9], which reframed senescence as a direct consequence of free radical reactions.

Metabolic and Telomeric Aging Paradigms era

Calvin B. Harley and 2 others

Calvin B. Harley[10] conducted research while affiliated with McMaster University[13] and Geron (United States)[14]. They contributed to the era's focus on cellular senescence by demonstrating in Telomeres shorten during ageing of human fibroblasts[16] that telomeres shorten progressively during the aging of human fibroblasts. Carol W. Greider[11] performed investigations at Cold Spring Harbor Laboratory[15] and McMaster University[13]. They advanced the understanding of telomere dynamics through Telomeres shorten during ageing of human fibroblasts[16], establishing how replicative aging correlates with chromosomal end-replication limitations. A. B. Futcher[12] worked at Cold Spring Harbor Laboratory[15] and McMaster University[13]. They provided critical evidence for the telomeric aging paradigm by co-authoring Telomeres shorten during ageing of human fibroblasts[16], linking cellular division history to the mechanisms of human aging.

Systems Biology of Aging era

David H. Salat and 3 others

David H. Salat[17] conducted research at the Athinoula A. Martinos Center for Biomedical Imaging[21] and Massachusetts General Hospital[22]. Through the work Thinning of the Cerebral Cortex in Aging[27], this investigator illuminated how brain aging phenotypes illustrate the processes shaping cognitive trajectories. C. Ronald Kahn[18] pursued investigations at the Joslin Diabetes Center[23] and Harvard University[24]. In Extended Longevity in Mice Lacking the Insulin Receptor in Adipose Tissue[28], this researcher advanced our understanding of how insulin and IGF-like signaling pathways act as central systemic regulators of lifespan. Matthias Blüher[19] contributed from Leipzig University[25] and the Joslin Diabetes Center[23]. Through Extended Longevity in Mice Lacking the Insulin Receptor in Adipose Tissue[28], this author helped establish endocrine signals as interdependent determinants of lifespan. Barbara B. Kahn[20] performed studies at Beth Israel Deaconess Medical Center[26] and Harvard University[24]. By publishing Extended Longevity in Mice Lacking the Insulin Receptor in Adipose Tissue[28], this scientist further demonstrated the role of insulin signaling pathways as central systemic regulators within the systems-level view of aging.

Senescence and Metabolic Aging Frameworks era

James L. Kirkland and Tamar Tchkonia

James L. Kirkland[29] conducted key research while affiliated with the Mayo Clinic in Florida[31] and the Mayo Clinic[32]. Through the seminal studies Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders[33], The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs[34], Targeting cellular senescence prevents age-related bone loss in mice[35], and Cellular senescence drives age-dependent hepatic steatosis[36], this work established cellular senescence as a central driver of tissue dysfunction and advanced therapeutic development by targeting senescent cells to mitigate age-related disorders. Tamar Tchkonia[30] contributed to the field while working at the Mayo Clinic in Florida[31] and the Mayo Clinic[32]. Via the foundational publications Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders[33], The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs[34], Targeting cellular senescence prevents age-related bone loss in mice[35], and Cellular senescence drives age-dependent hepatic steatosis[36], these investigations characterized the senescence-associated secretory phenotype and catalyzed translational strategies for clearing senescent cells to combat chronic inflammation and multi-system decline.